The Role of the Thymus in Myasthenia Gravis

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Completed
CT.gov ID
NCT01102192
Collaborator
NeuroCure Clinical Research Center, Charite, Berlin (Other)
20
1
64
0.3

Study Details

Study Description

Brief Summary

Although the association between thymic hyperplasia / thymoma and autoimmune myasthenia gravis has been known for some time, the question of causality remains uncertain. Recent research findings indicate, however, that especially in myasthenia patients with thymomas a non-physiological export of naive CD4 + T-cells can take place by the tumour and this could possibly play an important role in the pathogenesis of myasthenia gravis. The investigators want to analyse the functionality and specificity of t-cells generated in thymomas as well as the effect of thymectomy on the immune system.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    On one hand we want to perform a detailed analysis of the T-cells generated in thymomas in terms of their functional capacity and their specificity. We will analyse blood and thymoma tissue of patients with myasthenia gravis with thymona, patients with myasthenia gravis without thymona, and patients with thymona without myasthenia gravis.

    Hypothesis: The T-cells which are generated in the thymoma in thymoma-associated myasthenia gravis can be differentiated from T-cells which are generated in normal thymoma tissue with regard to functionality and T-cell receptor specificity. This non-physiological T-cell maturation might be the cause for the formation of auto-antibodies.

    On the other hand we want to examine the effects of thymectomy on the immune system in the context of myasthenia gravis. We will analyse blood and thymoma tissue of patients with myasthenia gravis with thymona, patients with myasthenia gravis without thymona, patients with thymona without myasthenia gravis and patients with cardiac, or thyroid surgery.

    Hypothesis:
    1. Thymectomy in patients with myasthenia gravis leads to a reduced number of auto-reactive, e.g. Acetylcholine receptor (ACh-R)-specific T cells. In contrast, T-cells with other specifities, for example against CMV or tetanus, are not affected.

    2. The non-physiological export of thymocytes from thymomas leads to a significant shift in leukocyte populations in peripheral blood.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    20 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Study Start Date :
    Aug 1, 2007
    Actual Primary Completion Date :
    Dec 1, 2012
    Actual Study Completion Date :
    Dec 1, 2012

    Arms and Interventions

    Arm Intervention/Treatment
    Myasthenia gravis with thymoma

    Myasthenia gravis with thymoma

    Myasthenia gravis without thymoma

    Myasthenia gravis without thymoma

    Thymoma without Myasthenia gravis

    Thymoma without Myasthenia gravis

    cardiac, or thyroid surgery

    cardiac, or thyroid surgery

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Patients with compelling indications for thymectomy due to thymoma (with or without myasthenia gravis), Or

      • Patients with elective indication for thymectomy due to thymoma without myasthenia gravis

      • Patients with indication for a heart or thyroid surgery, in which for op-technical reasons, a (partial) resection of the thymus is performed.

      • Signed informed consent form

      • Age > 17 Years

      Exclusion Criteria:
      • Other immunological diseases such as rheumatoid arthritis, multiple sclerosis

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Charite University (Dept of Neurology & NeuroCure Clinical Research Center NCRC) Berlin Germany 10117

      Sponsors and Collaborators

      • Charite University, Berlin, Germany
      • NeuroCure Clinical Research Center, Charite, Berlin

      Investigators

      • Principal Investigator: Andreas Meisel, MD, Charite University, Berlin, Germany

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Andreas Meisel, Prof. Dr., Charite University, Berlin, Germany
      ClinicalTrials.gov Identifier:
      NCT01102192
      Other Study ID Numbers:
      • Thymus in myasthenia gravis
      First Posted:
      Apr 13, 2010
      Last Update Posted:
      Jul 10, 2020
      Last Verified:
      Jul 1, 2020
      Keywords provided by Andreas Meisel, Prof. Dr., Charite University, Berlin, Germany
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Jul 10, 2020